The most recent 13F filing that Brinker Capital Investments LLC submitted to the Securities and Exchange Commission reveals that during the third quarter of this year, the company increased its holdings of Outset Medical, Inc. (NASDAQ: OM). Following the acquisition of an additional 3,949 shares of the company during the period under review, the total number of shares held by the fund in the company above now stands at 19,865. The most recent disclosure that Brinker Capital Investments LLC made to the SEC indicated that the company held an ownership stake in Outset Medical with a value of 316,000 dollars.
Recent changes have been made to the holdings of OM that several other hedge funds have made.
Point72 Hong Kong Ltd.
Invested $27,000 in Outset Medical during the second quarter to acquire additional company shares.
Increased its holdings in Outset Medical by a factor of 387.1 percent during the second quarter of the year.
Assetmark Inc. now has 1,812 shares, valued at $27,000, after making an additional purchase of 1,440 shares during the period in question. This brings the total number of shares owned by Assetmark Inc. to 2,040. Nisa Investment Advisors LLC completed the purchase of an additional 139.5% stake in Outset Medical during the second quarter, bringing the company’s total ownership stake to 100%. Nisa Investment Advisors LLC has a total ownership stake in the company equal to 2,060 shares after purchasing an additional 1,200 shares during the most recent period. The value of Nisa Investment Advisors LLC’s ownership stake in the company is $31,000. US Bancorp DE increased its Outset Medical holdings by 286.7% over the first three months of 2018. US Bancorp DE now holds a total of 2,711 shares of the company’s stock following the acquisition of an additional 2,010 shares during the most recent period.
Each share of the company’s stock is currently valued at $123,000.
At the end of the first quarter, Atria Wealth Solutions, Inc.
Invested in shares in the company Outset Medical valued at $226,000. The vast majority of the company’s stock is owned by institutional investors and hedge funds, which account for 98.84% of the total.
On Thursday, the first day of trading for OM shares, the price of which was $28.37, was established. Outset Medical, Inc. hit a low point over the past year of operations of $11.41 per share, while the company reached a 52-week high of $487 per share. The share price represents a market value of $1.37 billion, while the price-to-earnings ratio stands at -8.30, and the beta value sits at 1.50. The current ratio is 6.24, the quick ratio is 5.13, and the debt-to-equity ratio is 0.11. The ratio of current assets to current liabilities is 5.13. The company’s moving average over the previous 50 days is $24.11, and the moving average over the previous 200 days is $19.49.
The results report for the third quarter was published by Outset Medical on November 8th, marking the day the report was made public (NASDAQ: OM). The company reported that its earnings per share (EPS) for the quarter came in at $0.85, which was $0.03 less than the consensus estimate of $0.82 from market analysts. Outset Medical had a negative return on equity of 49.75%, and the company also had a negative net margin of 145.93%. The actual revenue for the quarter came in at $27.76 million, which was substantially higher than the estimate of $25.35 million for the same period. Outset Medical, Inc.
Is expected to report earnings of -3.43 cents per share for the current fiscal year, as stated by the projections made by equity research analysts.
Recently, several analysts released research that they had recently published on the company’s stock, which was released recently.
In a report distributed on November 9th, Goldman Sachs Group lowered their “buy” rating and price objective on the shares of Outset Medical to $29.00 and $34.00, respectively. This was done about the report that they had previously held.
In a report released on Tuesday, November 15th, Cowen announced that they would be decreasing their price target for the Outset Medical company to $22.00.
Morgan Stanley upgraded Outset Medical from an “equal weight” rating to an “overweight” rating and increased their price objective on the stock from $17.00 to $27.00 in a research report disseminated on Friday, January 6th.
According to research published on November 9th, Cowen decreased their price target for Outset Medical shares from $33.00 to $22.00. This news was shared with the investing community.
Last but not least, on November 11th, the Royal Bank of Canada started covering Outset Medical shares in a report they issued. That same day, the report was made public. They have given the company an “outperform” rating and determined that its price target should be $23.00. The stock has been given a rating of “buy” by four of the research analysts have rated the stock as ” buy, ” while one recommended that investors maintain their holdings in the stock.
According to Bloomberg.com, the consensus view regarding Outset Medical is that it is a “Moderate Buy” and that the average price objective for the stock is $24.50.
Additionally, the site reports that the average price target for the stock is $24.50.
On Friday, November 11th, the company’s CEO, Leslie Trigg, sold 30,000 shares of company stock. This is just one of the latest developments relating to this topic. There was a total transaction worth six hundred and fifty thousand dollars worth of shares sold at an average price of twenty dollars each. The transaction resulted in the company’s chief executive officer acquiring ownership of 291,159 shares, a total value of approximately $5,823,180. On the Securities and Exchange Commission (SEC) website, you can currently access the information submitted to the SEC in connection with the sale. On Friday, November 11, Chief Operating Officer Martin Vazquez sold 15,000 shares of company stock. This development is relevant to the discussion because it pertains to the topic.
A total of three hundred thousand dollars worth of stock was traded at an average price of twenty dollars per share, making the total transaction value three hundred thousand dollars.
After the completion of the transaction, the chief operating officer purchased a total of 49,550 shares of the company.
Based on the current market price, these shares have a value of approximately $990,000. On the Securities and Exchange Commission (SEC) website, you can currently access the information submitted to the SEC in connection with the sale.
On top of that, the company’s Chief Executive Officer, Leslie Trigg, sold 30,000 shares of company stock on Friday, November 11. There was a total transaction worth six hundred and fifty thousand dollars worth of shares sold at an average price of twenty dollars each. The chief executive officer currently holds a direct ownership stake in the business, equivalent to 2,911,159 shares. The current market price for these shares is approximately $5,823,180. The disclosure about the purchase can be found in this particular location.
In the past ninety days, employees and other insiders of the company have collectively sold 129,679 shares of company stock, bringing in a total of $2,814,251. Corporate insiders are the owners of 4.00% of the total shares outstanding.
Dialysis equipment, also known as a hemodialysis system, is one of the products manufactured by Outset Medical, Inc., a company that specializes in medical technology production.
It offers the Tablo Hemodialysis System, a compact console that features built-in water filtration, on-demand dialysate generation, software, and connectivity capabilities for hemodialysis treatment in medical facilities as well as in the privacy and convenience of one’s own home.
Leave a comment